ThromboGenics To Present at Key Investor Meetings

24 Mar 2016

4 Drug Candidates: Novel Disease Modifying Treatments for Diabetic Eye Disease,

1 Drug Candidate: Innovative Orphan Drug for Treatment of Pediatric Cancer


Leuven, 24 March 2016 – ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments for back of the eye disease, today announced that it will be presenting at several key investor meetings over the next few weeks and months.


  • Kempen & Co 9th European Healthcare & Life Sciences Conference on April 6 – 7, 2016 in Amsterdam
  • Invest Securities 10th European Smallcap Event  on April 11 – 12, 2016 in Paris
  • European Mid Small Cap Forum on May 18, 2016 in London
  • ING Belgian Day on June 7 – 8, 2016 in New York City
  • Jefferies 2016 Healthcare Conference on June 7 – 10, 2016 in New York City
  • Société Générale Healthcare & Biotechnology Conference on June 28, 2016 in Paris
  • European Mid Small Cap Forum on June 29 – 30, 2016 in Zurich

The announced roadshow plans follow the Company’s introduction of its new drug development pipeline first presented during last Friday’s ThromboGenics Research & Development Investor Meeting in London.


Over the past 18 months, ThromboGenics has developed a world class pipeline of disease modifying drug candidates for the treatment of diabetic eye disease.  The pipeline consists of THR-409 (ocriplasmin), THR-317 (anti-PlGF), THR-149 (plasma kallikrein inhibitor), which has resulted from a research collaboration with Bicycle Therapeutics, and THR-687 (integrin receptor antagonist), which was recently in-licensed from Galapagos.  With that, ThromboGenics will initiate several new clinical trials over the next 3-4 years, starting in 2016.

Next to its ambitious plans in ophthalmology, ThromboGenics is also progressing its commitments in oncology via its spin out Oncurious nv, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors. Last week’s announcement of the Oncurious partnership with NMTRC in the US, is a last step in the preparative work before initiating a Phase I/IIa clinical program with TB-403 for the treatment of medulloblastoma, a rare, life-threatening pediatric cancer. Further announcements are awaited.